Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HK2 | P52789 | 6/20 | 0.53 |
| ▸ | HK1 | P19367 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520981 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15965649 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966250 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966292 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL12371561 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL17210624 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL8930010 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966273 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15590477 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL13012256 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737469-A1 | NUCLEIC ACID CONJUGATES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Siran Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| US-12540323-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-02-03 | — | — | US | claimed |
| EP-4674965-A1 | SIRNA TARGETING INHIBIN ?E, SIRNA CONJUGATE, AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2026-01-07 | — | — | EP | claimed |
| US-12497622-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-12-16 | — | — | US | claimed |
| US-12496347-B2 | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-12-16 | — | — | US | claimed |
| EP-4628583-A1 | BICYCLIC ABASIC NUCLEIC ACID ANALOGS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-09-30 | — | — | US | claimed |
| CN-119925624-A | Liver targeting compound and conjugate, preparation method and application thereof | 上海数因信科智能科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4527459-A2 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-03-26 | — | — | EP | claimed |
| EP-4518902-A1 | BRANCHED LINKER FOR ASIALOGLYCOPROTEIN RECEPTOR LIGANDS | Guangzhou Ribobio Co., Ltd. (CN) | 2025-03-12 | — | — | EP | claimed |
| EP-3719128-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | claimed |
| EP-3719127-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | claimed |
| CN-111655297-A | siRNA conjugate and preparation method and application thereof | 苏州瑞博生物技术有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-111655849-A | Nucleic acid, pharmaceutical composition containing nucleic acid, conjugate and application of conjugate | 苏州瑞博生物技术有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-111377984-A | Compounds and conjugates and methods of making and using the same | 苏州瑞博生物技术有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-111377985-A | Compounds and conjugates and methods of making and using the same | 苏州瑞博生物技术有限公司 | 2020-07-07 | — | — | CN | claimed |
| WO-2020135581-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-07-02 | — | — | WO | claimed |
| CN-110959011-A | Conjugate, preparation method and application thereof | 苏州瑞博生物技术有限公司 | 2020-04-03 | — | — | CN | claimed |
| WO-2020063198-A1 | SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-04-02 | — | — | WO | claimed |
| WO-2020038377-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-02-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540323-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | PCSK9, APOB, NSUN2 | KDM4E 2139/4885LMNA 53/4885CYP2D6 2481/4885 |
| US-12497622-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | F13A1, F13B, F11 | KDM4E 3618/4885LMNA 91/4885CYP2D6 4008/4885 |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | TEK, TIE1, IGF2BP3 | KDM4E 2984/4885LMNA 422/4885CYP2D6 4304/4885 |
| US-12496347-B2 | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | APOB, PCSK9, APOL1 | KDM4E 3028/4885LMNA 256/4885CYP2D6 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.